These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36428627)

  • 1. Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.
    Acha P; Mallo M; Solé F
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics of myelodysplastic syndromes with del(5q) in Taiwan.
    Yang CF; Hsu CY; Hsiao LT; Chen SW; Chuang SS
    Malays J Pathol; 2023 Dec; 45(3):405-416. PubMed ID: 38155382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
    Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
    Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
    Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
    Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
    Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach.
    Acha P; Palomo L; Fuster-Tormo F; Xicoy B; Mallo M; Manzanares A; Grau J; Marcé S; Granada I; Rodríguez-Luaces M; Diez-Campelo M; Zamora L; Solé F
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
    Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
    Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.
    Beier F; Masouleh BK; Buesche G; Ventura Ferreira MS; Schneider RK; Ziegler P; Wilop S; Vankann L; Gattermann N; Platzbecker U; Giagounidis A; Götze KS; Nolte F; Hofmann WK; Haase D; Kreipe H; Panse J; Blasco MA; Germing U; Brümmendorf TH
    Leuk Res; 2015 Sep; ():. PubMed ID: 26427727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on cytogenetic and molecular changes in myelodysplastic syndromes.
    Schlegelberger B; Göhring G; Thol F; Heuser M
    Leuk Lymphoma; 2012 Apr; 53(4):525-36. PubMed ID: 21877899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and
    Hatzimichael E; Lagos K; Vassou A; Gougopoulou D; Papoudou-Bai A; Briasoulis E
    Mol Clin Oncol; 2016 Jul; 5(1):23-26. PubMed ID: 27330758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PP2A: The Achilles Heal in MDS with 5q Deletion.
    Sallman DA; Wei S; List A
    Front Oncol; 2014; 4():264. PubMed ID: 25295231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.